Tekmira Pharmaceuticals Corp (TKMR) (TKMR)

[Ubertino]

Tekmira Pharmaceuticals Corp’s “Buy” Rating Reaffirmed at Maxim Group (TKMR)

Posted by: Shayan Afkhami Posted date: June 18, 2013 In: Analyst Articles - US, Investing

Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)‘s stock had its “buy” rating reaffirmed by research analysts at Maxim Group in a report released on Tuesday, TheFlyOnTheWall.com reports. They currently have a $7.00 price target on the stock. Maxim Group’s price objective would suggest a potential upside of 45.83% from the stock’s previous close.

Shares of Tekmira Pharmaceuticals Corp (NASDAQ: TKMR) traded down 1.25% during mid-day trading on Tuesday, hitting $4.74. Tekmira Pharmaceuticals Corp has a one year low of $1.77 and a one year high of $6.78. The stock’s 50-day moving average is currently $4.55.

Tekmira is a leader in the development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (NASDAQ: TKMR).

http://www.mideasttime.com/tekmira-pharmaceuticals-corps-buy-rating-reaffirmed-at-maxim-group-tkmr/26169/